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Available online 5 November 2016Preimplantation genetic diagnosis (PGD) is widely applied in reciprocal translocation carriers to increase the
chance for a successful live birth. However, reciprocal translocation carrier embryos were seldom discriminated
from the normal ones mainly due to the technique restriction. Here we established a clinical applicable approach
to identify precise breakpoint of reciprocal translocation and to further distinguish normal embryos in PGD. In the
preclinical phase, rearrangement breakpoints and adjacent single nucleotide polymorphisms (SNPs) were char-
acterized by next-generation sequencing followingmicrodissecting junction region (MicroSeq) from 8 reciprocal
translocation carriers. Junction-spanning PCR and sequencing further discovered precise breakpoints. The precise
breakpoints were identiﬁed in 7/8 patients and we revealed that translocations in 6 patients caused 9 gene dis-
ruptions. In the clinical phase of embryo analysis, informative SNPs were chosen for linkage analyses combined
with PCR analysis of the breakpoints to identify the carrier embryos. From 15 blastocysts diagnosed to be chro-
mosomal balanced, 13 blastocysts were identiﬁed to be carriers and 2 to be normal. Late prenatal diagnoses for
ﬁve carriers and one normal fetus conﬁrmed the carrier diagnosis results. Our results suggest that MicroSeq
can accurately evaluate the genetic risk of translocation carriers and carrier screen is possible in later PGD
treatment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Preimplantation genetic diagnosis1. Introduction
Reciprocal translocations are one of themost common abnormalities
in chromosomal structure, with an incidence of 1/500 to 1/625 human
newborns (Ogilvie and Scriven, 2002). The origin of a reciprocal translo-
cation is associated with inherited or de novo nonhomologous chromo-
some rearrangements, and exposure to chemicals and radiation
(Tucker, 2008). It has been reported that N6% of reciprocal carriers
have a variety of symptoms, such as autism, intellectual disabilities, or
congenital abnormalities (Gersen et al., 2013). Most of them resulted
from microdeletions, duplications, or gene disruption in carriers
(Feenstra et al., 2011; Schneider et al., 2015). In addition, because of
quadrivalent formations during meiosis, reciprocal translocation car-
riers with normal phenotype are likely to produce gametes with unbal-
anced products, which usually result in recurrent miscarriage and
sometimes infertility. In these carriers, the genetic risk of reciprocal
translocations should be carefully investigated.d Stem Cell Engineering, School
ha 410078, China.
. This is an open access article underA preimplantation genetic diagnosis (PGD) offers an effective treat-
ment option for reciprocal translocation carriers to minimize the risk
and distress of pregnancy loss caused by abnormal chromosomal segre-
gation (Braude et al., 2002). Since the 1990s,ﬂuorescence in situ hybrid-
ization (FISH) (Scriven et al., 1998), array-based comparative genomic
hybridization (Alfarawati et al., 2011), and next-generation sequencing
(NGS) (Tan et al., 2014) have beenwidely used in PGDs to detect abnor-
mal copy numbers of chromosomal segments. In this scenario, both car-
rier and normal embryos had the same chance to be selected and result
in live births and theoretically half of the offsprings will likely to inherit
fertility problems. Furthermore, although reciprocal translocation do
not increase the risk of physical or mental disability for most inherited
balanced translocations (Gardner et al., 2012), the breakpoint in de
novo translocation carriers may interrupt functional genes which
might generate harmful effects in later life.
To date, some approaches have been developed to distinguish nor-
mal and carrier embryos via PGD. Patient-speciﬁc breakpoint-spanning
or closely ﬂanking FISH probes could be designed to detect both numer-
ical and structural aberrations in either interphase cells or in polar bod-
ies for PGD (Munne et al., 1998; Weier et al., 1999). Moreover, nuclear
transferring of human blastomere intomature bovine or mouse oocytes
could help to visualize metaphase chromosomes for full karyotyping inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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speciﬁc FISH probes design and optimization is time-consuming; and
blastomere nuclei conversion needs both sophisticated embryologists
for nuclei transfer and special cytogeneticists for single cell metaphase
harvest and karyotyping in heterokaryons. More recently, it was report-
ed that SNP array based comprehensive chromosome screening (CCS)
was successfully used to distinguish normal from balanced transloca-
tion carrier embryos formost carrier couples (Treff et al., 2016). Howev-
er, parental DNA and at least one unbalanced IVF embryo were
necessary for the diagnosis, and the genetic risk of carrier cannot be
evaluated since precise breakpoints were not identiﬁed. Currently
there are no effectivemethods for all carrier couples to precisely identify
breakpoints and/or linkage polymorphismmarkers for both carrier em-
bryo diagnosis and genetic risk evaluation.
Breakpoint identiﬁcation has been one of the most interesting ﬁelds
in cytogenetics for investigating the phenotypic outcomes of reciprocal
translocations. Several techniques had been developed tomap chromo-
some breakpoints to the kilobase level (Chen et al., 2008; Gribble et al.,
2009; Higgins et al., 2008; Sobreira et al., 2011; Talkowski et al., 2011;
Talkowski et al., 2012; Vergult et al., 2014). However, these techniques
are time-consuming, expensive, and do not provide information about
the breakpoint-linked SNPs for use in later PGDs. Recently, chromosome
microdissection followed by NGS has been reported for use in precisely
identifying the reciprocal translocation breakpoints at the level of the
individual base in a leukemia patient (Jancuskova et al., 2013). Here,
we describe the “MicroSeq-PGD” method, which combines previously
reported chromosome microdissection technique (Hu et al., 2007) and
NGS followed by PGD, to characterize the DNA sequence of the translo-
cation breakpoint and to distinguish between normal and carrier em-
bryos in 8 reciprocal translocation carriers (Fig. 1).
2. Materials and Methods
2.1. Study Patients
This clinical diagnostic study was reviewed and approved by the In-
stitutional Review Board (IRB) of the Reproductive andGenetic Hospital
of CITIC-Xiangya (LL-SC-SG-2014-013). Metaphase spreads, DNA sam-
ples and whole genome ampliﬁcation products of the patients were
used for breakpoint analyses and further PGD. The studywas conducted
in compliance with the provisions of the Declaration of Helsinki. All pa-
tients provided written informed consent before diagnosis. This study
included a total of 8 couples at the CITIC-Xiangya Hospital from July 1,
2014 to December 31, 2015. Eithermember of the couple had reciprocal
translocations (excluding Robertsonian translocations, where the
breakpoint is adjacent to the centromere). The karyotypes of the cou-
ples were determined from G-banded metaphase spreads obtained
from peripheral blood using standard techniques.
2.2. Chromosome Microdissection
Chromosome microdissection and PCR ampliﬁcation of the microdis-
sected DNA were performed as described previously (Hu et al., 2004).
Five to eight copies of the region covering the breakpoints were dissected
fromG-bandingmetaphase spreads of the patients' peripheral blood sam-
ples with glass needles. The dissected DNA fragments were ampliﬁed by
DOP-PCR with UN1 primer (CCGACTCGAGNNNNNNATGTGG). An initial
6 cycles of PCR (denaturation at 94 °C for 1 min, annealing at 30 °C for
2 min, and extension at 37 °C for 2 min) were performed by adding
0.3 units of T7 DNA polymerase (Sequenase Version 2.0, USB, Cleveland,
OH) at each cycle. A conventional PCR using Taq DNA polymerase was
then performed for 35 cycles (denaturation at 94 °C for 1 min, annealing
at 56 °C for 1 min, and extension at 72 °C for 2 min). Ampliﬁed DNA was
labeled with spectrum-green or spectrum-red dUTP (Vysis, Downers
Grove, IL) via PCR and then hybridized to metaphases from patients to
conﬁrm the success of chromosome microdissection.2.3. Next Generation Sequencing of DNA from Microdissected
Chromosomes
Breakpoint mapping was based on parallel sequencing with a
paired-end protocol and a bioinformatic analysis using the Integrative
Genomics Viewer (Robinson et al., 2011). Brieﬂy, 100 ng of ampliﬁed
microdissected DNA were fragmented by enzyme digestion and puri-
ﬁed to yield fragments of 100–500 bp. P1 adaptor oligonucleotides
from Life Tech were ligated on repaired A tailed fragments. About
150–300 bp fragments were separated, puriﬁed and enriched by elec-
trophoresis and PCR cycles. Genomic libraries were prepared using the
Ion Xpress library kit (Life Technologies Inc., Rockville, MD). Each DNA
library was then sequenced on a Life Tech. Ion Proton system with 318
chips as paired-end 200-bp reads. Image analysis and base calling was
performed using a Life Tech. 460 Flow system.
Sequence data were cleaned by removing the primer sequences and
thenwere aligned to the reference genome (hg19) using the Integrative
Genomics Viewer. Brieﬂy, those sequences that could not be aligned to
hg19 or aligned to multiple sites of hg19 were removed. SNPs were
compared with dbSNP and 1000 Genomes Project database (http://
www.1000genomes.org). The SNPs with a mutation frequency of
b40% were picked as candidate breakpoint-speciﬁc SNPs. The cleaned
sequence data were then aligned to hg19 with integrative genomics
viewer.
2.4. Precise Characterization of Breakpoints
We then synthesized speciﬁc primers that were supposed to be near
to the breakpoints to amplify the junction fragmentswith genomic DNA
from the translocation carriers. The PCR products were then sequenced
to precisely identify the accurate breakpoints by Sanger sequencing.
We also synthesized speciﬁc primers to amplify and then sequenced
the selected SNPs of the couples. Only the SNPs that were heterozygous
in the translocation carriers and homozygous in their normal partner
were considered as informative SNPs.
2.5. Comprehensive Chromosomal Screening
Preimplantation genetic diagnosis by comprehensive chromosomal
screening was performed as previously described (Tan et al., 2014).
Brieﬂy, pituitary desensitization was performed using a long luteal Go-
nadotropin-releasing hormone (GnRH) agonist protocol based on pa-
tient situations (Erb and Wakim, 2008). After oocyte retrieval, all eggs
were fertilized by intracytoplasmic sperm injection (ICSI). All embryos
were cultured in sequential media (G1 and G2, Vitrolife, Goteborg, Swe-
den) to the blastocyst stage. Approximately 3–8 trophectoderm (TE)
cells were aspirated using a biopsy pipette with a 30-μm internal diam-
eter and dissected with a Zilos TK laser (Hamilton Thorne, MA, USA).
Biopsied TE cells were then used for whole genome ampliﬁcation
(WGA) via multiple displacement ampliﬁcation with a REPLI-g Single
Cell Kit (Qiagen, Valencia, CA). NGS and comprehensive chromosomal
screening was then performed as previously described (Tan et al.,
2014).
2.6. Carrier Embryo Diagnosis
The excess WGA products were ampliﬁed with junction-spanning-
speciﬁc primers via PCR, with genomic DNA of translocation carriers
serving as the positive control and genomic DNA from healthy donors
serving as the negative control. The informative SNPs ﬂanking the
breakpoint were ampliﬁed via PCR and then sequenced to reduce the
risk of recombination. In the normal/carrier embryos diagnosed via
PGD-CCS, only the embryos that were identiﬁed as positive in the junc-
tion-spanning PCR analysis and/or those positive for informative SNPs
were predicted to be carrier embryos. The embryos that were negative
Fig. 1.Discrimination of normal and carrier embryos viaMicroSeq and PGD. Junction fragments of derivative chromosomesweremicrodissected and ampliﬁed via DOP-PCR. The ampliﬁed
DNA samples were sequenced using next generation sequencing. Precise breakpoints were determined via long-range PCR. Informative breakpoint-linked SNPs were identiﬁed in a
bioinformatics analysis and conﬁrmed by sequencing the selected SNPs in the couples. In the normal/carrier embryos diagnosed via PGD-CCS, only the embryos that were identiﬁed as
positive in the junction-spanning PCR analysis and/or those positive for informative SNPs were predicted to be carrier embryos. The embryos that were negative in the breakpoint and
junction-spanning PCR analyses and/or for informative SNPs were predicted to be normal embryos.
141L. Hu et al. / EBioMedicine 14 (2016) 139–147in the junction-spanningPCR analyses and/or for informative SNPswere
predicted to be normal embryos (Fig. 1).
2.7. Blastocyst Vitriﬁcation, Warming and Transfer
Blastocysts were vitriﬁed after the biopsy using Kitazato vitriﬁcation
solution (Kitazato Biopharma Co. Ltd. Shizuoka. Japan) and closed HighSecurity Vitriﬁcation straws (Cryo Bio System, France). Each blastocyst
was stored in an individual straw. After warming and dilution, blasto-
cystswere cultured in blastocystmedium for 1–2 h. Only chromosomal-
ly normal/balanced blastocysts were selected for warming, and the
surviving re-expanded blastocysts with high morphological grades
were selected for transfer. Luteal support was applied in cryopreserved
embryo transfer (CET) cycles. Warmed blastocysts were transferred
142 L. Hu et al. / EBioMedicine 14 (2016) 139–147either 5 days after ovulation during a natural menstrual cycle or 5 days
after the initiation of ovulation via progesterone administration. Brieﬂy,
6 mg Estradiol Valerate was started from Day 3 for 10–15 days, then lu-
teal support was applied when a satisfactory endometrial development
(thickness ≥ 8 mm) was conﬁrmed with ultrasound. No more than two
blastocysts were transferred, and single blastocyst transfer to each pa-
tient with well-cryopreserved embryos was recommended.Fig. 2. Reverse FISH of microdissected DNA. Reciprocal translocations of the eight patients are il
that all microdissected products cover rearrangement breakpoints (lower panel).2.8. Prenatal Diagnosis
Clinical pregnancy was conﬁrmed when an intrauterine gestational
sac with a heartbeat was observed via ultrasound examination 30–
40 days after embryo transfer. Amniocentesis was performed at 16–
18 weeks' gestation age. The amniocentesis ﬂuid samples from fetuses
were used for karyotyping to conﬁrm the PGD results.lustrated in the upper panel. Reverse FISH using ampliﬁed DNA fragment as probes shows
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3.1. MicroSeq Analysis
Totally 16 breakpoints for 8 translocation carriers were character-
ized. Reverse FISH using ampliﬁed DNA fragment as probes showed
that all microdissected products covered rearrangement breakpoints
(Fig. 2). The 16 ampliﬁed DNA samples were then sequenced at 1.76–
3.59million reads.We found that 17.3–56.4%of the readswere uniquely
aligned to the reference human genome (hg19). The coverage of aligned
reads to thedissected regions ranged from3.6–35.7%. Aftermapping the
same chromosomal sequences from two derivative chromosomes to-
gether, the breakpoints of each chromosomal translocation were
narrowed down to 24 bp-8.96 kbp (Table 1).
3.2. Breakpoint Characterization
To further characterize the precise sequence of the rearrangement
breakpoints, multiple PCR reactions spanning the narrowed-down re-
gions of the derivative chromosomes were performed, and the
amplicons were then sequenced to precisely identify the breakpoint se-
quences at the level of individual bases. We successfully identiﬁed 14
breakpoints in 7 patients. Interestingly, translocations in 6/7 patients
caused the disruption of 9 genes, including the disease-related genes
OLR1 and MERTK (Table 1). Fortunately, further sequencing revealed
that nomutationwas detected in these 9 genes of their healthy spouses.
Most breakpointswere in introns and hadmicrohomologous sequences,
deletions or insertions after the rearrangement (Fig. S1). For case 6,
with the t(6;22) translocation, the sequence from der(6) and der(22)
that mapped to the reference genome of chromosome 6p12.1 had a
1086 bp gap (55,492,412–55,493,498) after alignment. However, the
aligned sequence in 22q11.21 was located just inside a complex
palindromic region, which resulted in an overlap of 103,267 bp
(20,626,224–20,729,491) and a failure of junction-spanning PCR (Fig.
S2). Thus, the precise breakpoint in this patient could not be identiﬁed.
3.3. Breakpoint Adjacent SNPs Characterization
From the sequence information obtained for the ﬂanking rearrange-
ment breakpoints, we identiﬁed 12,564mutant SNPs in 8 patients, with
8–1453 SNPs per junction fragment (Table 1). We selected 244 SNPs
within 10 Mbp from the breakpoint and with a frequency of b40% in
the 1000 Genomes Project database as candidate SNPs for the linkage
analysis. The genotypes of selected SNPs in the balanced translocation
carriers and their spouses were further analyzed via sequencing.
Among them,we found that 124 SNPswere heterogeneous in the trans-
location carriers and homogenous in their spouses, which means that
these were informative SNPs. With these SNPs, we successfully
established partial haplotypes near the breakpoints of the derivative
chromosomes in all 8 couples, with 2–17 SNPs per derivative chromo-
some (Table S1).
3.4. Preimplantation Genetic Diagnosis
The 8 couples recruited in this study received 10 PGD treatment cy-
cles. A total of 45 blastocysts were biopsied for WGA. Biopsy TE cells
from 44 blastocysts were successfully ampliﬁed. After comprehensive
chromosome screening via NGS, 26 out of the 44 blastocysts had trans-
location-related abnormalities, 3 blastocysts showed de novo aneuploi-
dy unrelated to translocation, and the other 15 blastocysts were
balanced, indicating that they were either normal or had balanced
translocation (Table S2).
We then performed a PCR analysis that spanned the breakpoints,
and we ampliﬁed the breakpoint-adjacent informative SNPs for se-
quencing analysis with the rest of theWGA products to distinguish nor-
mal blastocysts from blastocysts with balanced translocations. In total,124 SNPs within 10 Mbp of the rearrangement breakpoints were suc-
cessfully analyzed. We then performed linkage analysis with the infor-
mative SNPs in 44 embryos of 8 patients. The total effective detection
frequency is 593. Interestingly, recombinations were only observed at
distances N5 Mbp from the breakpoint, from 0% (0/305) at b5 Mbp re-
gion to 4.45% (13/288) at N5 Mbp region (Table S3). Thus, informative
SNPswithin 5Mbp could be probably used to diagnose carrier embryos.
The linkage analysis showed that 13 blastocysts were balanced translo-
cation carriers, and only 2 blastocystswere normal (Tables S1 and S2). A
junction-spanning PCR analysiswas performed on 12blastocysts from7
patients whose rearrangement breakpoints had been successfully iden-
tiﬁed. Breakpoints were detected in 10 blastocysts, indicating that they
were carrier embryos. The other two embryos were negative, indicating
normal embryos. The junction-spanning PCR results showed 100%
agreement with the previous linkage analysis results.
3.5. Clinical Outcome
Before completing the analysis, 7 patients had already had their fro-
zen embryos transferred. Nine blastocysts were thawed, and 8 blasto-
cysts survived. Seven transfer cycles were performed, and 4 women
became pregnant. In one woman, the pregnancy ended at 45 days
after the embryo transfer (ET) in her ﬁrst cycle, but she successfully be-
came pregnant at the second ET. After prenatal diagnosis via amniocen-
tesis, all of the babieswere diagnosed as balanced translocation carriers.
To date, ﬁve healthy babies with balanced translocation have been suc-
cessfully delivered. These results agreewith previous predictions (Table
S2). For case 8, the carrier analysis results came out before her frozen
embryo was transferred. She had 4 balanced blastocysts: three blasto-
cysts were predicted to be carrier embryos and only one to be normal.
After giving informed consent, the patient decided to have the normal
blastocyst transferred, and a successful pregnancy was established. A
prenatal diagnosis conﬁrmed that the fetus had a normal karyotype
(Fig. 3). Furthermore, for all 29 chromosomal unbalanced embryos, ex-
istence of derivative chromosomes predicted by junction-spanning PCR
and/or breakpoint-adjacent informative SNPs analysis was consistent
with that was predicted by PGD-CCS (Table S2). The above results also
proved the accuracy of our PGD approach based onMicroSeq technique.
4. Discussion
PGD is currently used to exclude chromosomally unbalanced embry-
os and to ensure a successful live birth for balanced translocation car-
riers with an unfortunate obstetric history or infertility. Although a
variety of techniques have been developed to identify carrier embryos
in PGD, the efﬁciency and consistence performance of these techniques
between individuals hampered their clinical applications. In this scenar-
io, embryos with normal karyotypes from translocation carriers cannot
be preferentially transferred and one half of the offsprings would theo-
retically inherit the translocation-bearing chromosomes and may face
reproductive difﬁculties in the future. Moreover, the genetic risk caused
by de novo reciprocal translocation was not investigated routinely in
phenotypically normal carriers. In the current study, usingMicroSeq ap-
proach, we were generally able to precisely map rearrangement
breakpoints to the level of individual bases. Compare with other avail-
able techniques, this approach combines chromosome microdissection
and NGS techniques. Precise dissection of chromatin covering
breakpoint minimizes the following NGS cost. NGS of ampliﬁed dissect-
ed DNA can reliably and accurately obtain sequence of junction frag-
ments, which help to precisely identify the breakpoint as well as
nearby SNPs. It takes only 5 days for chromosome microdissection,
and regular library construction protocol is suitable for the following
NGS.
Inmost cases, we found thatmultiple genes were disrupted and that
some potential pathogenic genes were affected by balanced transloca-
tions. Although most interrupted genes in this study are recessive,
Table 1
Summary of breakpoint characterization results of the eight patients
Patient Carrier karyotypea der chr No. of
mapped
sequencing
reads
Coverage
(%)
Distance of
the nearest
NGS mapping
reads to
breakpoint
(bp)
Total_Mutation
SNP numbers
Identifying
linked to
breakpoint
informative
SNPs number
Breakpoint position from
Sanger sequencing
Disrupt
gene
(break
region)
OMIM
ID
Gene Ontology
1 46,XX,t(4;17)(q32.3;q21.2) der(4) 4 50,516 3.59 2,347 58 2 chr4:169,227,027-169,227,031 DDX60
(Intron
5/37)
613974 Nucleic acid binding and
hydrolase activity17 167,018 5.41 3,506 74 0
der(17) 4 34,792 6.35 1,514 43 6 chr17:40,053,060-4,005,3061 ACLY
(Intron
13/28)
108728 Cofactor binding and ATP citrate
synthase activity17 81,784 10.45 2,258 31 4
2 46,XY,t(3;12)(q25.2;p13.2),inv(9)(p11q13) der(3) 3 169,432 9.89 818 428 3 chr3:153,121,850-153,121,851 – – –
12 175,243 19.14 614 328 7
der(12) 3 349,210 12.12 1,144 130 0 chr12:10,311,870-10,311,877 OLR1
(Exon
4/4)
602601 Carbohydrate binding and
low-density lipoprotein receptor
activity
12 206,640 20.02 1,177 100 0
3 46,XX,t(4;15)(q23;q22.2) der(4) 4 156,036 9.66 898 149 2 chr4:100,891,783-100,891,784 – – –
15 215,786 9.23 206 176 4
der(15) 4 440,532 9.27 561 517 3 chr15:60,310,881-60,310,896 FOXB1
(Intron
1/2)
– Transcription factor activity,
sequence-speciﬁc DNA binding
and RNA polymerase II
transcription factor activity,
sequence-speciﬁc DNA binding
15 241,418 10.21 1,045 186 5
4 46,XX,t(1;2)(p31.1;q13) der(1) 1 735,087 23.73 223 87 1 chr1:70,936,280-70,936,290 – – –
2 203,356 16.74 2,045 162 3
der(2) 1 183,725 14.14 167 1,214 8 chr2:112,661,491-112,661,518 MERTK
(Intron
1/18)
604705 Transferase activity, transferring
phosphorus-containing groups
and protein tyrosine kinase
activity
2 158,214 18.75 1,362 358 5
5 46,XY,t(8;20)(p21.3;q13.33) der(8) 8 215,633 30.18 250 161 7 chr8:22,991,894-22,991,895 – – –
20 11,242 26.68 0 8 0
der(20) 8 189,386 15.74 2,210 223 4 chr20:61,754,133-61,754,134 – – –
20 310,178 18.2 6,750 518 7
6 46,XY,t(6;22)(p12.1;q11.21) der(6) 6 36,694 24.12 NA 57 0 – – – –
22 89,584 10.4 NA 50 2
der(22) 6 675,112 29.86 NA 1,194 3 – – – –
22 101,853 22.44 NA 183 2
7 46,XX,t(4;9)(q21.23;q21.13) der(4) 4 572,409 35.73 0 856 9 chr4:84,877,905-84,877,912 BC005018
(Intron
7/7)
– NA
9 550,854 31.51 24 1,236 8
der(9) 4 555,651 16.84 302 1,072 8 chr9:75,640,607-75,640,608 ALDH1A1
(Intron
1/12)
100640 Oxidoreductase activity and
acyl-CoA dehydrogenase activity9 76,442 25.86 121 160 4
8 46,XY,t(9;17)(q31.3;q25.3) der(9) 9 152,030 6.1 880 102 2 chr9:114,402,958-114,402,959 DNAJC25
(Intron
1/4)
– Signal transducer activity
17 27,428 5.74 925 15 0
der(17) 9 590,926 32.54 1,490 1,235 7 chr17:76,740,337-76,740,338 CYTH1
(Intron
1/12)
182115 Lipid binding and ARF
guanyl-nucleotide exchange
factor activity
17 898,244 31.53 160 1,453 8
a Carrier karyotypes in this table have been revised following the breakpoint mapping information and the original G-band karyotypes are provided in Table S2.
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Fig. 3. PGD and carrier diagnosis of a t(9;17) patient. In total, 7 embryoswere obtained and analyzed. Based on complete chromosome screening, embryos 1, 2, 4, and 7were identiﬁed as
normal/carrier embryos, whereas embryos 3, 5, and 6were identiﬁed as unbalanced embryos (a). Junction-spanning PCR analysis of whole-genome ampliﬁcation products from embryos
showed that embryos 1, 4, and 7 were positive and that embryo 2 was negative (b), indicating that only embryo 2 was a normal embryo, while the other 3 embryos were carriers. SNP
analysis conﬁrmed that only embryo 2 was negative for informative SNPs (red) characters in panel (c). The normal blastocyst was transferred after the subject gave informed consent,
and a successful pregnancy was established. Prenatal diagnosis conﬁrmed that the fetus had a normal karyotype (d).
145L. Hu et al. / EBioMedicine 14 (2016) 139–147balanced translocation offsprings may suffer from genetic defects if an-
other allele had pathogenic mutations or deletions. In the 9 disrupted
genes from the 8 patients, homozygous loss of function of Acly,
DDX60, Fkh5 and Aldh1a1 were associated with lethal in early embryo
development (Beigneux et al., 2004),defects in antiviral immune re-
sponse (Oshiumi et al., 2015), severe growth retardation (Wehr et al.,
1997) and sensitivity for retinol toxicity (Molotkov and Duester,
2003) respectively. Moreover, MERTK, a recessive gene that had been
associatedwith retinal dystrophy (McHenry et al., 2004), was disrupted
in another patient. Fortunately, in the follow-up study there was no ge-
netic mutation detected in those disrupted genes in the healthy spouse
genome. Taking the above observations into consideration, although no
discernible increased risk of clinical abnormality was observed in the
children with the same balanced translocation karyotype as in their
asymptomatic carrier parents (Gardner et al., 2012), our data suggest
that potential genetic risks may exist in phenotypically normal de
novo translocation carriers. Considering the risks of further reproduc-
tive difﬁculties and the potential genetic risks, it is worthy to character-
ize and evaluate the breakpoint-affected genes ahead. Nevertheless, the
signiﬁcance of gene interruption should be evaluated and consulted by
professional genetic consultants, especially regarding genes of un-
known signiﬁcance and cancer predisposition genes.In this study, we observed a bias of carrier to non-carrier embryos
with a ratio of 13:2. However, limited sample size may account for
this bias. Treff and colleagues evaluated 126 balanced embryos in PGD
by SNP array based CCS. Among them, 62 (49%) were predicted to be
normal embryos and 64 (51%)were predicted as balanced translocation
carrier embryos (Treff et al., 2016). Thus,more data and appropriate sta-
tistical methods are needed to measure the carrier to non-carrier em-
bryo ratio. Moreover, it is important to inform that a non-carrier
embryo is no guarantee in any one PGD cycle, and a carrier embryo
could also be transferred if no further genetic risk is detected.
In this study, the number of informative SNPswas highly viable from
breakpoint to breakpoint. The ampliﬁcation efﬁciency of DOP-PCR may
account for this variation. However, there are enough informative SNPs
for further PGD for embryoswith balanced translocations.Moreover,we
only included the SNPswith N10× coverage in this study. Sincemore in-
formative SNPswillminimize the impact of allelic dropout to ensure the
PGD accuracy, SNPs with b10× coverage could also be tested and in-
cluded to increase thenumber of SNPs for further PGD. For Robertsonian
translocations, although it is difﬁcult to ﬁnd exact breakpoints that lo-
cated in cetromeric region, nearby informative SNPs linkage analysis
will help to discriminate normal embryos and embryos with balanced
Robertsonian translocations. However, the position of informative
146 L. Hu et al. / EBioMedicine 14 (2016) 139–147SNPs should be carefully investigated to avoid recombination-caused
misdiagnosis.
Although the breakpoints in 22q11.21 in one patient were not iden-
tiﬁed due to interference from complex palindromic sequences, we suc-
cessfully characterized the SNPs adjacent to the rearrangement
breakpoints in all patients. The guidelines of the European Society of
Human Reproduction and Embryology suggest that extragenic markers
within 1 Mbp of a mutation should be included in PGDs to reduce mis-
takes caused by recombination, as the probability for recombination
within 1 Mbp is low (Harton et al., 2011). However, according to our
linkage analysis, data from 44 embryos from reciprocal carriers show
that recombination events were not observedwithin 5Mbp of the rear-
rangement breakpoint. It is possible that the increased distance of the
homologous chromatids in the center of the quadrivalent reduced the
chances of recombination in the ﬂanking sequences of the rearrange-
ment breakpoints. This ﬁnding enabled us to obtain more informative
SNPs over a relatively wider area for use in PGDs. This also makes a
less-detailed MicroSeq sequencing step practical.
In this study, we succeeded in developing a reliable approach for
performing linkage and junction-spanning PCR analyses to distinguish
normal and carrier embryos in a PGDbased on the information provided
by a MicroSeq analysis. This approach has been shown to be effective
based on the prenatal validation of the initial diagnoses. However, the
sensitivity and speciﬁcity of this approach should be evaluated in a larg-
er sample size. In addition, this approach may also provide a future
means of diagnosing embryos that are carriers of Robertsonian translo-
cations and inversions during PGDs.
Supplementary data to this article can be found online at doi:10.
1016/j.ebiom.2016.11.007.
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